Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company, announced that its CEO, Arthur T. Sands, M.D., Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:45 pm PT. The presentation will cover Nurix's 2022 achievements and goals for 2023. A live webcast of the presentation will be available on the company’s website, with an archived version accessible for 30 days post-event. Nurix focuses on developing targeted therapies for cancer through E3 ligase modulation.

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix’s achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT.

The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Silinda Neou
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When will Nurix Therapeutics present at the J.P. Morgan Healthcare Conference?

Nurix Therapeutics will present on January 9, 2023, at 3:45 pm PT.

What will Nurix's CEO discuss at the conference?

The CEO will discuss the company's achievements in 2022 and major goals for 2023.

How can I watch the Nurix Therapeutics presentation?

The presentation will be webcast live, accessible via the Investors section of the Nurix website.

Will the Nurix presentation be available later?

Yes, an archived version will be available on the Nurix website for 30 days following the event.

What is the focus of Nurix Therapeutics?

Nurix is focused on developing targeted protein modulation therapies for hematologic malignancies and solid tumors.